Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials

Dulaglutide

(2015) Angela M. Thompson et al.   ANNALS OF PHARMACOTHERAPY

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

(2014) Guillermo Umpierrez et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

(2014) Carol Wysham et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

(2014) Michael Nauck et al.   DIABETES CARE

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)

(2014) Z. Skrivanek et al.   DIABETES OBESITY & METABOLISM

Dulaglutide: First Global Approval

(2014) Mark Sanford   DRUGS

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects

(2011) P. Barrington et al.   DIABETES OBESITY & METABOLISM

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes

(2011) P. Barrington et al.   DIABETES OBESITY & METABOLISM

Neonatal Fc receptor and IgG-based therapeutics

(2011) Timothy T. Kuo et al.   mAbs

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Population Pharmacokinetics of Liraglutide, a Once-Daily Human Glucagon-Like Peptide-1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice-Daily Exenatide

(2010) Estelle Watson et al.   JOURNAL OF CLINICAL PHARMACOLOGY